293 related articles for article (PubMed ID: 30925338)
41. Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
Usui Y; Uehara F; Hiki S; Watanabe K; Tanaka H; Shouda A; Yokoshima S; Aritomo K; Adachi T; Fukunaga K; Sunada S; Nabeno M; Saito KI; Eguchi JI; Yamagami K; Asano S; Tanaka S; Yuki S; Yoshii N; Fujimura M; Horikawa T
Bioorg Med Chem Lett; 2017 Aug; 27(16):3726-3732. PubMed ID: 28712708
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
43. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Zhang L; Zhao J; Zhang B; Lu T; Chen Y
Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
[TBL] [Abstract][Full Text] [Related]
44. Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors.
Gentile G; Bernasconi G; Pozzan A; Merlo G; Marzorati P; Bamborough P; Bax B; Bridges A; Brough C; Carter P; Cutler G; Neu M; Takada M
Bioorg Med Chem Lett; 2011 Aug; 21(16):4823-7. PubMed ID: 21764580
[TBL] [Abstract][Full Text] [Related]
45. Towards discovery of new leishmanicidal scaffolds able to inhibit
Martínez de Iturrate P; Sebastián-Pérez V; Nácher-Vázquez M; Tremper CS; Smirlis D; Martín J; Martínez A; Campillo NE; Rivas L; Gil C
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):199-210. PubMed ID: 31752556
[TBL] [Abstract][Full Text] [Related]
46. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
47. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening.
Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757
[TBL] [Abstract][Full Text] [Related]
48. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
[TBL] [Abstract][Full Text] [Related]
49. Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.
Koryakova AG; Ivanenkov YA; Ryzhova EA; Bulanova EA; Karapetian RN; Mikitas OV; Katrukha EA; Kazey VI; Okun I; Kravchenko DV; Lavrovsky YV; Korzinov OM; Ivachtchenko AV
Bioorg Med Chem Lett; 2008 Jun; 18(12):3661-6. PubMed ID: 18502121
[TBL] [Abstract][Full Text] [Related]
50. 6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.
Uehara F; Shoda A; Aritomo K; Fukunaga K; Watanabe K; Ando R; Shinoda M; Ueno H; Kubodera H; Sunada S; Saito K; Kaji T; Asano S; Eguchi J; Yuki S; Tanaka S; Yoneyama Y; Niwa T
Bioorg Med Chem Lett; 2013 Dec; 23(24):6928-32. PubMed ID: 24094818
[TBL] [Abstract][Full Text] [Related]
51. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
More KN; Hong VS; Lee A; Park J; Kim S; Lee J
Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
[TBL] [Abstract][Full Text] [Related]
52. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
53. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
54. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
Im D; Jung K; Yang S; Aman W; Hah JM
Eur J Med Chem; 2015 Sep; 102():600-10. PubMed ID: 26318067
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.
Chun K; Park JS; Lee HC; Kim YH; Ye IH; Kim KJ; Ku IW; Noh MY; Cho GW; Kim H; Kim SH; Kim J
Bioorg Med Chem Lett; 2013 Jul; 23(13):3983-7. PubMed ID: 23683591
[TBL] [Abstract][Full Text] [Related]
56. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
Gao Y; Ye DY; Zhou WC; Chu Y
Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
[TBL] [Abstract][Full Text] [Related]
57. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
58. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
[TBL] [Abstract][Full Text] [Related]
59. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
60. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.
Rippin I; Khazanov N; Shirley Ben Joseph ; Kudinov T; Berent E; Arciniegas Ruiz SM; Marciano D; Levy L; Gruzman A; Senderowitz H; Eldar-Finkelman H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
